ATNM

Actinium Pharmac

• TipRanks·4h ago

  Actinium Pharmaceuticals’ ATNM-400 shows anti-tumor activity in prostate cancer

• PR Newswire·5h ago

  Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer

• Benzinga·5h ago

  Actinium Pharmaceuticals Presents New Preclinical Data From Its ATNM-400 Across Non-Small Cell Lung Cancer At 39th Annual Congress Of European Association Of Nuclear Medicine

• TipRanks·6h ago

  Pantginis Reiterates Buy on ATNM-400 Following HER3 Target Disclosure and Early Phase 1 Data; $4 Price Target Maintained

• Benzinga·23h ago

  12 Health Care Stocks Moving In Monday's Intraday Session

• Benzinga·1d ago

  Actinium Pharmaceuticals To Present Data And Preclinical Results For ANTM-400 At The Congress Of The European Association Of Nuclear Medicine, October 17–21

• Dow Jones·3d ago

  Press Release: Actinium Pharmaceuticals Announces Inducement Grants to New Employees

• PR Newswire·3d ago

  Actinium Pharmaceuticals Announces Inducement Grants to New Employees

• Benzinga·4d ago

  Actinium Pharma To Present Preclinical Data Supporting ATNM-400's Broad Potential At 39th Annual Congress Of EANM

• TipRanks·4d ago

  Actinium Pharmaceuticals to present ATNM-400 data at EANM

• Dow Jones·4d ago

  Press Release: Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development

• PR Newswire·5d ago

  Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer

• Seeking Alpha·5d ago

  Actinium Pharmaceuticals names former CorMedix executive as CFO

• NASDAQ·5d ago

  Actinium Pharmaceuticals Names Matt David CFO

• Dow Jones·5d ago

  *Actinium Pharmaceuticals David Joins From CorMedix Where He Most Recently Served as Chief Business Officer >ATNM